Loading organizations...

FluidAI Medical is a technology company.
FluidAI Medical develops intelligent systems for post-operative care, leveraging advanced sensing and machine learning to improve surgical recovery. Their core product, Stream Care™, is an all-in-one system that integrates electronic health record data with insights from proprietary hardware like Origin™ to predict the risk of post-operative complications after gastrointestinal surgery. Origin™ itself attaches to surgical drains, continuously monitoring biochemical fluid composition to enable early detection of anastomotic leakage, thereby supporting informed clinical decision-making.
The company was co-founded by Youssef Helwa, Amr Abdelgawad, Abdallah El-Falou, and Mohamed Okasha, initially as NERv Technology. Youssef Helwa and Amr Abdelgawad met at the University of Waterloo in 2011, establishing the venture stemming from a fourth-year design project. Helwa's personal connection to surgery through his mother's profession and his background in nanotechnology engineering fueled the insight to apply novel sensor technology and artificial intelligence to prevent post-surgical complications.
FluidAI Medical serves hospitals seeking to enhance patient outcomes and optimize surgical workflows. The company envisions a future where real-time, data-driven intelligence empowers care teams to proactively manage patient recovery, significantly reducing the incidence and severity of complications. Their long-term objective is to transform post-operative monitoring by providing clinicians with actionable insights for safer and more efficient surgical care.
FluidAI Medical has raised $18.8M across 3 funding rounds.
FluidAI Medical has raised $18.8M in total across 3 funding rounds.
FluidAI Medical has raised $18.8M in total across 3 funding rounds.
FluidAI Medical's investors include SOSV, Nabil Alnoor Borhanu, Boutique Venture Partners, Cur8 Capital, Juno Pharmaceuticals, Kyto Technology & Life Science, Leva Capital, ThresholdImpact, Graphene Ventures, NorthSpring Capital Partners, OneValley Ventures, Sunhope Venture Capital.
FluidAI Medical is a Canadian medtech company founded in 2014 (formerly NERv Technology) that develops AI-driven platforms for postoperative surgical care, focusing on general and gastrointestinal surgeries.[1][2][3] Its flagship product, Origin, is an inline sensing device that connects to surgical drains to monitor effluent in real-time for early detection of complications like leaks and infections, integrating with the AI-powered Stream Care suite for predictive analytics and decision support.[2][5] Serving hospitals and clinicians, FluidAI addresses postoperative risks by combining proprietary sensors, EHR data, and AI to enable proactive interventions, reducing complications, hospital stays, and costs—having raised $20.25M total, with recent FDA 510(k) clearance in September 2025 marking strong growth momentum.[2][3][5]
FluidAI Medical originated in Kitchener, Ontario, Canada, in 2014 as NERv Technology, initially supported by HAX accelerator for prototyping and industrial design to reach its first product iteration.[2][4] The idea stemmed from harnessing AI and sensors to analyze surgical drain fluid for early complication detection, validated through animal trials that demonstrated feasibility and led to a 2019 pre-seed raise.[4] Pivotal moments include rebranding to FluidAI, building a multidisciplinary team of clinicians, engineers, and data scientists, amassing one of the world's largest surgical datasets, and securing FDA clearance for Origin in 2025, enabling U.S. market entry and integration with broader platforms.[1][4][5]
FluidAI rides the wave of AI-enabled precision medicine and proactive postoperative monitoring, capitalizing on surging demand for data-driven healthcare amid rising surgical volumes and complication costs (e.g., infections prolonging stays).[1][5] Timing aligns with post-pandemic emphasis on efficiency, EHR digitization, and regulatory tailwinds like FDA clearance, amid market forces favoring interoperable medtech that cuts readmissions by 20-30% via early detection.[5] It influences the ecosystem by pioneering effluent-based biomarkers, partnering with hospitals/academics for research, and building dataset "banks" to expand beyond GI/general surgery—setting standards for AI-surgical integration and enabling scalable, value-based care models.[4][6]
FluidAI is poised for U.S. commercialization post-FDA nod, with Stream Care-Origin integration accelerating pilots and revenue as hospitals prioritize complication reduction.[5] Trends like multimodal AI, biomarker expansion, and nanotechnology will shape its path toward broader indications (e.g., cardiology, oncology), leveraging its dataset moat for new monitoring paradigms.[4] Influence may evolve into a platform leader, powering ecosystem-wide digital surgery via partnerships—transforming reactive recovery into proactive, personalized care and redefining medtech impact from Kitchener to global health systems.[1][6]
FluidAI Medical has raised $18.8M across 3 funding rounds. Most recently, it raised $15.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $15.0M Series A | SOSV, Nabil Alnoor Borhanu | Boutique Venture Partners, Cur8 Capital, Juno Pharmaceuticals, Kyto Technology & Life Science, Leva Capital, ThresholdImpact |
| Apr 1, 2020 | $3.0M Seed | SOSV | Boutique Venture Partners, Graphene Ventures, NorthSpring Capital Partners, OneValley Ventures, ThresholdImpact |
| Oct 16, 2019 | $760K Pre-Seed | Sunhope Venture Capital |